Advertisement

Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Primer for Internists

      Abstract

      Inflammatory bowel disease consists of disorders characterized by chronic idiopathic bowel inflammation. The concept of host–gut–microbiome interaction in the pathogenesis of various complex immune-mediated chronic diseases, including inflammatory bowel disease, has recently generated immense interest. Mounting evidence confirms alteration of intestinal microflora in patients with inflammatory bowel disease. Thus, restoration of normal gut microbiota has become a focus of basic and clinical research in recent years. Fecal microbiota transplantation is being explored as one such therapeutic strategy and has shown encouraging results in the management of patients with inflammatory bowel disease.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Naidoo K.
        • Gordon M.
        • Fagbemi A.O.
        • Thomas A.G.
        • Akobeng A.K.
        Probiotics for maintenance of remission in ulcerative colitis.
        Cochrane Database Syst Rev. 2011; (CD007443)
        • Fujiya M.
        • Ueno N.
        • Kohgo Y.
        Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials.
        Clin J Gastroenterol. 2014; 7: 1-13
        • Kassam Z.
        • Lee C.H.
        • Yuan Y.
        • Hunt R.H.
        Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis.
        Am J Gastroenterol. 2013; 108: 500-508
        • Siegel C.A.
        • Whitman C.B.
        • Spiegel B.M.R.
        • et al.
        Development of an index to define overall disease severity in IBD.
        Gut. 2018; 67: 244-254
        • Wang Y.
        • Parker C.E.
        • Bhanji T.
        • Feagan B.G.
        • MacDonald J.K.
        Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
        Cochrane Database Syst Rev. 2016; (CD000543)
        • Lim W.C.
        • Wang Y.
        • MacDonald J.K.
        • Hanauer S.
        Aminosalicylates for induction of remission or response in Crohn's disease.
        Cochrane Database Syst Rev. 2016; (CD008870)
        • Akobeng A.K.
        • Zhang D.
        • Gordon M.
        • MacDonald J.K.
        Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease.
        Cochrane Database Syst Rev. 2016; (CD003715)
        • Rutgeerts P.
        • Sandborn W.J.
        • Feagan B.G.
        • et al.
        Infliximab for induction and maintenance therapy for ulcerative colitis.
        N Engl J Med. 2005; 353: 2462-2476
        • Hanauer S.B.
        • Feagan B.G.
        • Lichtenstein G.R.
        • et al.
        Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
        Lancet. 2002; 359: 1541-1549
        • Feagan B.G.
        • Rutgeerts P.
        • Sands B.E.
        • et al.
        Vedolizumab as induction and maintenance therapy for ulcerative colitis.
        N Engl J Med. 2013; 369: 699-710
        • Sandborn W.J.
        • Feagan B.G.
        • Rutgeerts P.
        • et al.
        Vedolizumab as induction and maintenance therapy for Crohn's disease.
        N Engl J Med. 2013; 369: 711-721
        • Feagan B.G.
        • Sandborn W.J.
        • Gasink C.
        • et al.
        Ustekinumab as induction and maintenance therapy for Crohn's disease.
        N Engl J Med. 2016; 375: 1946-1960
        • Long M.D.
        • Martin C.F.
        • Pipkin C.A.
        • Herfarth H.H.
        • Sandler R.S.
        • Kappelman M.D.
        Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.
        Gastroenterology. 2012; 143 (390.e391-399.e391)
        • Herrinton L.J.
        • Liu L.
        • Weng X.
        • Lewis J.D.
        • Hutfless S.
        • Allison J.E.
        Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
        Am J Gastroenterol. 2011; 106: 2146-2153
        • Fréling E.
        • Baumann C.
        • Cuny J.F.
        • et al.
        Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
        Am J Gastroenterol. 2015; 110: 1186-1196
        • Ford A.C.
        • Peyrin-Biroulet L.
        Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials.
        Am J Gastroenterol. 2013; 108: 1268-1276
        • Lynch S.V.
        • Pedersen O.
        The human intestinal microbiome in health and disease.
        N Engl J Med. 2016; 375: 2369-2379
        • Sellon R.K.
        • Tonkonogy S.
        • Schultz M.
        • et al.
        Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice.
        Infect Immun. 1998; 66: 5224-5231
        • Rutgeerts P.
        • Goboes K.
        • Peeters M.
        • et al.
        Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum.
        Lancet. 1991; 338: 771-774
        • Selby W.
        • Pavli P.
        • Crotty B.
        • et al.
        Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease.
        Gastroenterology. 2007; 132: 2313-2319
        • Darfeuille-Michaud A.
        • Neut C.
        • Barnich N.
        • et al.
        Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease.
        Gastroenterology. 1998; 115: 1405-1413
        • Autschbach F.
        • Eisold S.
        • Hinz U.
        • et al.
        High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn's disease.
        Gut. 2005; 54: 944-949
        • Manichanh C.
        • Rigottier-Gois L.
        • Bonnaud E.
        • et al.
        Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach.
        Gut. 2006; 55: 205-211
        • Morgan X.C.
        • Tickle T.L.
        • Sokol H.
        • et al.
        Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment.
        Genome Biol. 2012; 13: R79
        • Gevers D.
        • Kugathasan S.
        • Denson L.A.
        • et al.
        The treatment-naive microbiome in new-onset Crohn's disease.
        Cell Host Microbe. 2014; 15: 382-392
        • Atarashi K.
        • Tanoue T.
        • Oshima K.
        • et al.
        Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota.
        Nature. 2013; 500: 232-236
        • Sokol H.
        • Pigneur B.
        • Watterlot L.
        • et al.
        Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients.
        Proc Natl Acad Sci U S A. 2008; 105: 16731-16736
        • Rodemann J.F.
        • Dubberke E.R.
        • Reske K.A.
        • Seo D.H.
        • Stone C.D.
        Incidence of Clostridium difficile infection in inflammatory bowel disease.
        Clin Gastroenterol Hepatol. 2007; 5: 339-344
        • Hamilton M.J.
        • Weingarden A.R.
        • Sadowsky M.J.
        • Khoruts A.
        Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection.
        Am J Gastroenterol. 2012; 107: 761-767
        • Kelly C.R.
        • Ihunnah C.
        • Fischer M.
        • et al.
        Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients.
        Am J Gastroenterol. 2014; 109: 1065-1071
        • Khoruts A.
        • Rank K.M.
        • Newman K.M.
        • et al.
        Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection.
        Clin Gastroenterol Hepatol. 2016; 14: 1433-1438
        • Fischer M.
        • Kao D.
        • Kelly C.
        • et al.
        Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease.
        Inflamm Bowel Dis. 2016; 22: 2402-2409
        • Kashani A.
        • Shih D.
        Fecal microbiota transplantation is highly effective for treatment of Clostridium difficile infection in patiants with inflammatory bowel disease; a meta-analysis.
        Gastroenterology. 2017; 152: S988
        • Kunde S.
        • Pham A.
        • Bonczyk S.
        • et al.
        Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis.
        J Pediatr Gastroenterol Nutr. 2013; 56: 597-601
        • Kump P.K.
        • Gröchenig H.P.
        • Lackner S.
        • et al.
        Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis.
        Inflamm Bowel Dis. 2013; 19: 2155-2165
        • Paramsothy S.
        • Kamm M.
        • Walsh A.
        • et al.
        Multi donor intense faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: a randomised placebo-controlled trial.
        Gastroenterology. 2016; 150: S122-S123
        • Moayyedi P.
        • Surette M.G.
        • Kim P.T.
        • et al.
        Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial.
        Gastroenterology. 2015; 149 (102.e106-109.e106)
        • Costello S.P.
        • Waters O.
        • Bryant R.V.
        • et al.
        Short duration, low intensity, pooled fecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial.
        Gastroenterology. 2017; 152: S198-S199
        • Rossen N.G.
        • Fuentes S.
        • van der Spek M.J.
        • et al.
        Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis.
        Gastroenterology. 2015; 149 (110.e114-118.e114)
        • Paramsothy S.
        • Paramsothy R.
        • Rubin D.T.
        • et al.
        Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis.
        J Crohns Colitis. 2017; 11: 1180-1199
        • Vaughn B.P.
        • Vatanen T.
        • Allegretti J.R.
        • et al.
        Increased intestinal microbial diversity following fecal microbiota transplant for active Crohn's disease.
        Inflamm Bowel Dis. 2016; 22: 2182-2190
        • Cui B.
        • Feng Q.
        • Wang H.
        • et al.
        Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results.
        J Gastroenterol Hepatol. 2015; 30: 51-58
        • Suskind D.L.
        • Brittnacher M.J.
        • Wahbeh G.
        • et al.
        Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease.
        Inflamm Bowel Dis. 2015; 21: 556-563
        • Vermeire S.
        • Joossens M.
        • Verbeke K.
        • et al.
        Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease.
        J Crohns Colitis. 2016; 10: 387-394
        • Pascal V.
        • Pozuelo M.
        • Borruel N.
        • et al.
        A microbial signature for Crohn's disease.
        Gut. 2017; 66: 813-822
        • Travis S.P.
        Review article: the management of mild to severe acute ulcerative colitis.
        Aliment Pharmacol Ther. 2004; 20: 88-92
        • Paramsothy S.
        • Kamm M.A.
        • Kaakoush N.O.
        • et al.
        Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.
        Lancet. 2017; 389: 1218-1228
        • Ishikawa D.
        • Sasaki T.
        • Osada T.
        • et al.
        Changes in intestinal microbiota following combination therapy with fecal microbial transplantation and antibiotics for ulcerative colitis.
        Inflamm Bowel Dis. 2017; 23: 116-125
        • Jacob V.
        • Crawford C.
        • Cohen-Mekelburg S.
        • et al.
        Single delivery of high-diversity fecal microbiota preparation by colonoscopy is safe and effective in increasing microbial diversity in active ulcerative colitis.
        Inflamm Bowel Dis. 2017; 23: 903-911
        • Lee C.H.
        • Steiner T.
        • Petrof E.O.
        • et al.
        Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial.
        JAMA. 2016; 315: 142-149
        • Miquel S.
        • Martín R.
        • Rossi O.
        • et al.
        Faecalibacterium prausnitzii and human intestinal health.
        Curr Opin Microbiol. 2013; 16: 255-261
        • Ji S.K.
        • Yan H.
        • Jiang T.
        • et al.
        Preparing the gut with antibiotics enhances gut microbiota reprogramming efficiency by promoting xenomicrobiota colonization.
        Front Microbiol. 2017; 8: 1208
        • Hintze K.J.
        • Cox J.E.
        • Rompato G.
        • et al.
        Broad scope method for creating humanized animal models for animal health and disease research through antibiotic treatment and human fecal transfer.
        Gut Microbes. 2014; 5: 183-191
        • Keshteli A.H.
        • Millan B.
        • Madsen K.L.
        Pretreatment with antibiotics may enhance the efficacy of fecal microbiota transplantation in ulcerative colitis: a meta-analysis.
        Mucosal Immunol. 2016; 10: 565-566
        • Schwartz M.
        • Gluck M.
        • Koon S.
        Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts.
        Am J Gastroenterol. 2013; 108: 1367
        • Hohmann E.L.
        • Ananthakrishnan A.N.
        • Deshpande V.
        Case records of the Massachusetts General Hospital. Case 25-2014. A 37-year-old man with ulcerative colitis and bloody diarrhea.
        N Engl J Med. 2014; 371: 668-675
        • Quera R.
        • Espinoza R.
        • Estay C.
        • Rivera D.
        Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection.
        J Crohns Colitis. 2014; 8: 252-253
        • Qazi T.
        • Amaratunga T.
        • Barnes E.L.
        • Fischer M.
        • Kassam Z.
        • Allegretti J.R.
        The risk of inflammatory bowel disease flares after fecal microbiota transplantation: systematic review and meta-analysis.
        Gut Microbes. 2017; 8: 574-588
      1. Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies.
        (Available at:)
        • Kahn S.A.
        • Vachon A.
        • Rodriquez D.
        • et al.
        Patient perceptions of fecal microbiota transplantation for ulcerative colitis.
        Inflamm Bowel Dis. 2013; 19: 1506-1513
        • Hourigan S.K.
        • Chen L.A.
        • Grigoryan Z.
        • et al.
        Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease.
        Aliment Pharmacol Ther. 2015; 42: 741-752
        • Kao D.
        • Roach B.
        • Silva M.
        • et al.
        Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial.
        JAMA. 2017; 318: 1985-1993